Stock 002550 CHANGZHOU QIANHONG BIOPHARMA CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Changzhou Qianhong Biopharma CO.,LTD

Equities

002550

CNE100001070

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
5.55 CNY -0.36% Intraday chart for Changzhou Qianhong Biopharma CO.,LTD -1.94% -5.61%
May. 22 Changzhou Qianhong Biopharma CO.,LTD Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
Apr. 26 Changzhou Qianhong Biopharma CO.,LTD Proposes Final Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2019 2021 2022 2023 2024 2025 2026
Capitalization 1 5,862 6,181 8,012 7,525 6,961 - -
Enterprise Value (EV) 1 5,862 6,181 8,012 7,525 6,961 6,961 6,961
P/E ratio 21.8 x 32.2 x 25 x 42 x 23.1 x 19.1 x 16.2 x
Yield - - - 2.04% 3.24% 1.89% 4.32%
Capitalization / Revenue 3.5 x - - 4.15 x 3.8 x 2.97 x 2.72 x
EV / Revenue 3.5 x - - 4.15 x 3.8 x 2.97 x 2.72 x
EV / EBITDA 15.9 x - - 27.1 x 16.1 x 13.8 x 11.8 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book 2.51 x - - 3.07 x 2.76 x 2.49 x 2.46 x
Nbr of stocks (in thousands) 1,279,975 1,279,800 1,279,800 1,279,800 1,249,800 - -
Reference price 2 4.580 4.830 6.260 5.880 5.550 5.550 5.550
Announcement Date 2/27/20 4/22/22 4/14/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2021 2022 2023 2024 2025 2026
Net sales 1 1,675 - - 1,814 1,831 2,347 2,562
EBITDA 1 368.1 - - 277.3 431.2 504.4 589.9
EBIT 1 300.2 - - 204.4 343.3 417.8 495.6
Operating Margin 17.92% - - 11.26% 18.75% 17.8% 19.35%
Earnings before Tax (EBT) 1 300.5 - - 203.5 343.6 418 496.3
Net income 1 262.6 181.1 323.4 181.9 302.8 371.5 438.6
Net margin 15.67% - - 10.02% 16.54% 15.83% 17.12%
EPS 2 0.2100 0.1500 0.2500 0.1400 0.2400 0.2900 0.3433
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - 0.1200 0.1800 0.1050 0.2400
Announcement Date 2/27/20 4/22/22 4/14/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) 10.7% - - 7.47% 11.7% 13.1% 15.3%
ROA (Net income/ Total Assets) - - - - 11% 11.5% 13.1%
Assets 1 - - - - 2,753 3,230 3,348
Book Value Per Share 2 1.820 - - 1.920 2.010 2.230 2.250
Cash Flow per Share 2 0.1300 - - 0.4200 0.3300 0.4400 0.3600
Capex 1 99 - - 68 154 92 154
Capex / Sales 5.91% - - 3.75% 8.41% 3.92% 6.01%
Announcement Date 2/27/20 4/22/22 4/14/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Changzhou Qianhong Biopharma CO.,LTD

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.55 CNY
Average target price
6.48 CNY
Spread / Average Target
+16.76%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD Stock Changzhou Qianhong Biopharma CO.,LTD
-5.61% 960M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.79% 780B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.76% 627B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.43% 334B
ABBVIE INC. Stock AbbVie Inc.
+7.18% 296B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.60% 244B
ROCHE HOLDING AG Stock Roche Holding AG
-0.41% 217B
NOVARTIS AG Stock Novartis AG
+11.54% 214B
AMGEN INC. Stock Amgen Inc.
+4.53% 161B
PFIZER, INC. Stock Pfizer, Inc.
-3.92% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002550 Stock
  4. Financials Changzhou Qianhong Biopharma CO.,LTD